Tenax Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
LEVEL trial completed enrollment ahead of schedule, with results expected in Q3 and strong patient retention. The global LEVEL-2 trial will expand reach and duration, while regulatory strategy focuses on robust safety and efficacy data. Cash runway and infrastructure support ongoing growth.
-
Phase III trials for levosimendan in PH-HFpEF are progressing globally, with robust patient enrollment and strong statistical power. The drug shows significant clinical benefits, high patient compliance, and targets a large, underserved market with a differentiated oral therapy profile.
Fiscal Year 2025
-
LEVEL phase III trial enrollment increased to 230, with results expected in the second half of next year. Both LEVEL 1 and LEVEL 2 use rigorous design, identical patient criteria, and a 3 mg oral dose, with LEVEL 2 expanding globally and extending to 26 weeks. Open-label extensions ensure patient access.
-
Phase III enrollment for PH-HFpEF is underway, with a second global trial starting soon and data expected in the second half of next year. The drug targets wedge pressure and has shown efficacy in prior studies, with a large addressable market and funding secured through 2027.
-
Experts highlighted TNX-103's unique mechanism and strong clinical data in PH-HFpEF, emphasizing its differentiation from failed vasodilator and Relaxin trials. The oral formulation showed improved patient outcomes, robust patent protection, and potential as an add-on therapy.
-
Levosimendan is advancing in phase 3 trials for PH-HFpEF, targeting a large unmet market with no approved therapies. The oral formulation shows sustained patient benefit, strong adherence, and promising clinical endpoints, with global expansion and robust IP protection.
-
A late-stage oral therapy for group two pulmonary hypertension is advancing through two global Phase III trials, targeting a $10B market with no approved treatments. Strong legacy data, successful transition from IV to oral, and robust trial design underpin confidence, with key milestones expected through 2027.
-
A novel oral therapy for PH-HFpEF is in Phase III, with expanded trials and strong FDA alignment. Phase II data showed significant improvements in exercise tolerance, and the addressable market is estimated at $10 billion. Investor and payer interest is high.
-
Leadership highlighted robust clinical and regulatory progress, including expanded phase 3 trials for oral levosimendan in PH-HFpEF, strong patient adherence, and a large market opportunity. Patent protection extends to 2042, and funding is secured through 2027.
-
Levosimendan is advancing in phase III trials for PH-HFpEF, targeting a large unmet need with a novel oral formulation. Market research shows strong physician and payer interest, and the regulatory focus is on symptom improvement. A first-to-market position is expected to drive adoption.